Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 28, 2019 - Issue 2
Submit an article Journal homepage
625
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluation

Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?

Mark L. ZangardiDepartment of Pharmacy, Massachusetts General Hospital, Boston, USAView further author information
,
Laura M. SpringMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USAView further author information
,
Aiko NagayamaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USAView further author information
&
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USACorrespondence[email protected]
View further author information
Pages 107-112 | Received 04 Aug 2018, Accepted 29 Nov 2018, Published online: 17 Dec 2018

References

  • American Cancer Society. Global cancer facts & figures. 3rd ed. Atlanta: American Cancer Society; 2015.
  • Paredes-Aracil E, Palazón-Bru A, Folgado-de la Rosa DM, et al. A scoring system to predict breast cancer mortality at 5 and 10 years. Sci Rep. 2017;7(1):415.
  • Nakano M, Fujisue M, Tashima R, et al. Survival time according to year of recurrence and subtype in recurrent breast cancer. Breast. 2015;24(5):588–593.
  • Gong Y, Liu Y, Ji P, et al. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep. 2017;7(45411):1–10.
  • NCCN Clinical Practice Guidelines in Oncology. Breast cancer. V4.2017; 2018 [cited 2018 Feb 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
  • Gretchen GL, Burke A, Anderson WF. Epidemiology of triple negative breast cancers. Breast Dis. 2010;32(1–2):5–24.
  • Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161:279–287.
  • Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer. 2016;10:25–36.
  • Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogenous disease. Nat Rev Clin Oncol. 2016;13(11):674–690.
  • Stepan LP, Trueblood ES, Hale K, et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011;59(7):701–710.
  • Shvartsur A, Bonavida B. Trop2 and its overexpression in cancer: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6(3–4):84–105.
  • Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9(48):28989–29006.
  • Ambrogi F, Fornili M, Broacchi P, et al. Trop-2 is a determinant of breast cancer survival. PLoS One. 2014;9(5):e96993. [Erratum: PLoS One 9: e110606, 2014].
  • NCI Dictionary of Cancer Terms. [cited 2018 Feb 2]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antibody-drug-conjugate
  • Nagayama A, Ellisen LW, Chabner B, et al. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Targ Oncol. 2017;12:719–739.
  • Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res. 2015;21(22):5131–5138.
  • Camptosar (irinotecan) prescribing information. [cited 2018 Feb 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf
  • Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Re. 1991;51:4187–4191.
  • Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123(19):3843–3854.
  • Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35(19):2141–2148.
  • Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417.
  • Xie R, Mathijssen RH, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther. 2002;72(3):265–275.
  • Li Z, Qiu Y, Lu W, et al. Immunotherapeutic interventions of triple negative cancer. J Transl Med. 2018;16(1):147.
  • Sussman D, Smith LM, Anderson ME, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014;13(12):2991–3000.
  • Modi S, Pusztai L, Forero A, et al. Phase 1 study of the antibody-drug conjugate ladiratuzumab vedotin (SGN-LIV1A) in patients with heavily pretreated triple-negative metastatic breast cancer. Presented at: 2016 San Antonio Breast Cancer Symposium; 2017 December 5–9; San Antonio, Texas. Abstract PD3-14.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.